Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + actinomycin-d
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
toripalimab + actinomycin-d is a combination therapy consisting of toripalimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and actinomycin-D (also known as dactinomycin), a cytotoxic chemotherapy agent. This regimen is being evaluated as a first-line treatment for patients with high-risk gestational trophoblastic neoplasia (GTN), specifically those with a FIGO score of 7. Toripalimab acts as an immune checkpoint inhibitor to enhance the body's anti-tumor immune response, while actinomycin-D inhibits transcription by intercalating into DNA and interfering with RNA polymerase. The combination is currently under investigation in a Phase II clinical trial led by Peking Union Medical College Hospital to assess its efficacy in achieving complete response and its safety profile in this patient population.
- Other names
- Toripalimab and Actinomycin-DToripalimab plus Actinomycin-DToripalimab/Actinomycin-D
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + actinomycin-d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + actinomycin-d.